NiCord is an expanded cell graft from umbilical cord blood, enriched with stem cells, developed with Gamida's NAM technology

Florida Hospital Pepin Heart Institute, of Tampa, has participated in two studies in heart stem cell therapy research...The results showed therapy with bone marrow-derived stem cells does not improve short-term recovery after a heart attack

The Phase IIa/b study, completed in December 2011, involved the use of a proprietary autologous stem cell formulation (Monocell) indicated for neoangiogeneses

Each will be injected with 100,000 human embryonic stem cell-derived retinal pigment epithelial cells...Optimer Pharmaceuticals Inc., of Jersey City, N.J., said the first patient was dosed in its DEFLECT-1, Phase IIIb trial of Dificid (fidaxomicin) tablets for the prevention of Clostridium difficile-associated diarrhea (CDAD) in patients undergoing hematopoietic stem cell transplant (HSCT

Bioheart Inc., of Sunrise, Fla., said it will start its ANGEL trial in Mexico and said NorthStart Biotech LLC, a consortium of Bioheart directors and shareholders, agreed to fund the study, which will test the safety and efficacy of LipiCell (adipose-derived stem cells) in congestive heart failure patients

StemCells Inc., of Newark, Calif., said two papers reporting clinical and preclinical data demonstrating the therapeutic potential of the company's HuCNS-SC cells (purified human neural stem cells) for a range of myelination disorders were published in the Oct. 10, 2012, edition of Science Translational Medicine...The other paper summarized preclinical research, which demonstrated that transplantation of neural stem cells in an animal model of severe myelin deficiency results in new myelin that

Moreover, according to the protocol for both trials, each patient in the second cohort will be injected with 100,000 human embryonic stem cell-derived retinal pigment epithelial cells, up from 50,000 in the first cohort. (See BioWorld Today, Nov. 23, 2011...Neuralstem Inc., of Rockville, Md., updated data from the Phase I trial to test its NSI-566 spinal cord stem cells in the treatment of amyotrophic lateral sclerosis

StemCells Inc., of Newark, Calif., said the first patient was enrolled in its Phase I/II study designed to test the safety and preliminary efficacy of the firm's HuCNS-SC product candidate (purified human neural stem cells) in dry age-related macular degeneration

Athersys Inc., of Cleveland, completed enrollment of the first patient cohorts in its Phase II study of MultiStem, its adult stem cell therapy for administration to patients within approximately one to two days following an ischemic stroke

Neuralstem Inc., of Rockville, Md., gained the go-ahead to start a clinical trial in motor deficits due to ischemic stroke with its spinal cord stem cells (NSI-566) at BaYi Brain Hospital in Beijing, through its subsidiary, Neuralstem China (Suzhou Neuralstem Biopharmaceutical Co. Ltd...StemCells Inc., of Newark, Calif., said the first patient with an incomplete spinal cord injury has been enrolled in the company's Phase I/II trial in chronic spinal cord injury and transplanted with the company's

The randomized, double-blind trial, known as AETHERA, is comparing Adcetris against placebo in patients at high risk of residual Hodgkin lymphoma following autologous stem cell transplant...In 2011, the FDA gave accelerated approval to Adcetris for Hodgkin lymphoma after the failure of either autologous stem cell transplant or at least two multi-agent chemotherapy regimens in transplant-ineligible patients and for systemic anaplastic large cell lymphoma after the failure of at least one multi-agent

Gamida Cell Ltd., of Jerusalem, said it completed enrollment in a Phase I/II study of NiCord, an expanded cell graft derived from an entire unit of umbilical cord blood enriched with stem cells

AlloCure Inc., of Burlington, Mass., said it started a Phase II trial of AC607, its mesenchymal stem cell therapy as a potential treatment for acute kidney injury...StemCells Inc., of Newark, Calif., said interim six-month data from the first patient cohort in its Phase I/II trial of HuCNS-SC (purified human neural stem cells) for chronic spinal cord injury continued to demonstrate a favorable safety profile and showed considerable gains in sensory function in two of the three patients, compared to

America Stem Cell Inc., of San Antonio, said it started a single-center study testing ASC-101 in dual-umbilical cord transplantation in patients with hematologic malignancies...Neuralstem Inc., of Rockville, Md., completed a Phase I trial of NSI-566 spinal cord neural stem cells for amyotrophic lateral sclerosis

Advanced Cell Technology Inc., of Marlborough, Mass., added Scotland's NHS Lothian as a site for its Phase I/II trial testing retinal pigment epithelial cells derived from human embryonic stem cells in Stargardt's macular dystrophy...The biologic product's design encodes stromal cell-derived factor 1, which is thought to repair tissue through recruitment of circulating stem cells to the site of injury, as well as preventing cell death

The patent-pending combination of two FDA-approved drugs is designed to mobilize mesenchymal stem cells from the bone marrow to the peripheral circulation, with the goal of reducing inflammation and increasing angiogenesis to restore liver function

Tumors from post-vaccine resections in five patients also showed a decrease in or loss of the cancer stem cell-associated antigen CD133 relative to pre-vaccine counterparts

University Hospitals Case Medical Center, in Cleveland, plans to conduct a U.S. Phase II study examining the safety and effectiveness of the adult stem cell therapy product MultiStem, developed by Athersys Inc., of Cleveland, in ischemic stroke

Advanced Cell Technology Inc., of Marlborough, Mass., treated its fourth patient, or the first in a second cohort, in a Phase I/II trial for dry, age-related macular degeneration with its human embryonic stem cell-derived retinal pigment epithelial cells